Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04462471 · ClinicalTrials.gov registry record · Phase 1
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04462471: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04462471 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04462471, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a new drug treatment to reverse tumor resistance to radioiodine in BRAF mutant tumors so that radioiodine can be given to shrink tumors. This study is also being done to find out the highest doses of copanlisib and vemurafenib that, when given in combination, do not cause serious side effects, and whether the study treatment will make radioiodine therapy work better in patients with BRAF-mutant thyroid cancers.
Interventions
- DRUG Vemurafenib
- DRUG Copanlisib
- DIAGNOSTIC_TEST I-124 PET/CT lesion dosimetry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-06-26 |
| Est. Completion | 2023-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04462471
The ClinicalTrials.gov registry entry for NCT04462471 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vemurafenib is the first listed.
NCT04462471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04462471 about?
NCT04462471 is a clinical study titled "Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers". The purpose of this study is to develop a new drug treatment to reverse tumor resistance to radioiodine in BRAF mutant tumors so that radioiodine can be given to shrink tumors. This study is also being done to find out the highest doses of copanlisib and vemurafenib that, when given in combination, ...
What is the current status of trial NCT04462471?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-06-26. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT04462471?
The interventions under investigation include: Vemurafenib (DRUG), Copanlisib (DRUG), I-124 PET/CT lesion dosimetry (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04462471?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.